Locomotor therapy with extended-release crystalline glucocorticoids

Abstract

Topical glucocorticoid (GC) therapy for locomotor diseases is an extremely important component of a comprehensive program to treat inflammatory and, to a lesser extent, degenerative diseases. It reduces the time of hospitalization by 5—10 days in this category of patients, has a prompt and potent anti-inflammatory effect, and shows predictable efficiency. This therapy shows good tolerability and high safety and prevents serious adverse reactions to GC treatment.

Keywords

• locomotor diseases
• extended-release crystalline glucocorticoids